You are using an older browser version. Please use a supported version for the best MSN experience.

Better Healthcare Stock: Teladoc vs. Doximity

The Motley Fool logo The Motley Fool 7/24/2021 Taylor Carmichael
Better Healthcare Stock: Teladoc vs. Doximity © Provided by The Motley Fool Better Healthcare Stock: Teladoc vs. Doximity

Teladoc Health (NYSE: TDOC) has been an amazing stock for long-term investors. The company was founded in 2002 and went public in 2015. In its S-1, Teladoc billed itself as "the nation's first and largest telehealth platform." Simply put, Teladoc is a website where people can visit with a doctor online. The company's website is a virtual hospital, open 24/7. You can talk with a doctor within minutes. For speedy and convenient healthcare, few businesses offer what Teladoc can. The stock is up over 420% since its IPO.

Are companies still trying to beat Teladoc? Yes they are. Amazon (NASDAQ: AMZN) is one such competitor. The e-commerce and cloud services giant is now entering the healthcare market on the insurance and pharmacy businesses. But perhaps the scariest news for Teladoc investors is that Doximity (NYSE: DOCS) just went public, and the company boasts some numbers that suggest it might be the stronger stock going forward.

Two people look at a smartphone while consulting with a doctor via video chat. © Getty Images Two people look at a smartphone while consulting with a doctor via video chat.

Doximity has a lot of optionality

Like Teladoc, Doximity has a simple business that's easy to explain. It's a digital platform for doctors. The website is designed to help doctors network and communicate with each other. It's the Facebook of healthcare. Eighty percent of American doctors are already on Doximity, and 90% of graduating medical students are on the site.

If you think about the power of networking for a second, you realize how valuable Doximity might become. Are 90% of medical students going to work for Teladoc? No. Are 90% of medical students going to work for Amazon? No. Who has captured all those medical eyeballs? Doximity. So if you want to reach doctors, it's a great place to start.

When COVID-19 hit last year and virtual healthcare took off, Doximity decided it would be a good idea to help all the doctors on its platform make virtual visits with their patients. So Doximity rolled it out. And the doctors on its platform used it for 63 million virtual visits with patients over the last 12 months. That's a shocking number, because it's almost six times higher than what Teladoc did in 2020.

Company Number of Virtual Visits in 12 Months Annual Revenue Quarterly Revenue Growth Profit Margin
Teladoc 11 million $1.3 billion 151% (48%)
Doximity  63 million $206 million 83% 24%

Data sources: Teladoc Health, Doximity, and Yahoo! Finance. Teladoc's recent fiscal year ended Dec. 31, 2020 and Doximity's recent fiscal year ended March 31, 2021.

Those are some interesting comps, right? Teladoc brings in six times more in revenue than Doximity, and is growing almost twice as fast. Yet Doximity had way more virtual visits than Teladoc. And the other shocking stat is that Doximity, despite its rapid revenue growth, is already highly profitable. Use the black ink to write out 24%, and use the red to mark Teladoc's 48% loss.

Indirect competition is dangerous

Of course, Teladoc has many direct competitors, companies like the horribly named American Well (Amwell) (NYSE: AMWL). (How's your stock doing? I fell down an American Well.) In tech stocks and internet companies, it's often wise to avoid the No. 2, the No. 3, or the No. 4. Those stocks tend to get obliterated as the top dog continues to dominate and seize market share.

chart, line chart: AMWL © YCharts AMWL

While Teladoc investors have little to fear from all the copycats trying to compete directly with the company, it's possible that the whole business model will be blown up by Doximity's virtual website. It's the problem with indirect competition -- you often don't see the challenge until it's too late.

Doximity is free (at first) 

Doximity is a free website -- that's how it's gotten so many doctors into its network. Teladoc is trying to build out a network of physicians that it can market to health insurers and other healthcare payers. Doximity already has that network in place.

Of course, these networks are quite different. Doximity's (much larger) network is made up of physicians and other healthcare providers. Doximity pays doctors nothing to join its network -- it just gives doctors free tools to use, including the capacity for virtual visits with patients. 

Teladoc is trying to become an employer of doctors, a virtual hospital. It cuts checks to all the doctors in its network. Doximity is the opposite of that. It doesn't pay doctors anything. Indeed, for some of Doximity's advanced tools, it actually charges doctors a fee. 

So it's obvious which company has a stronger value proposition for doctors. Just follow the money. Teladoc has to pay money to doctors to get them to join the network. But Doximity is so high up on the value chain, doctors happily pay it money.  

What about patients? Again, Doximity is the stronger value. Both companies offer virtual healthcare. But Doximity offers virtual visits with your primary care physician. Teladoc can't do that. So for people who want a relationship with their doctor, who want to "keep their doctor," Doximity is a no-brainer. 

Doximity is a more valuable company to doctors, and arguably a more valuable company to patients as well. Ultimately, I think the two market caps will reflect this valuation disparity, and that Doximity will be the stronger stock going forward.

SPONSORED:

10 stocks we like better than Doximity, Inc.

When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now… and Doximity, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of June 7, 2021

 

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to its CEO, Mark Zuckerberg, is a member of The Motley Fool's board of directors. Taylor Carmichael owns shares of Amazon and Doximity, Inc. The Motley Fool owns shares of and recommends Amazon, Amwell, Facebook, and Teladoc Health. The Motley Fool recommends the following options: long January 2022 $1,920 calls on Amazon and short January 2022 $1,940 calls on Amazon. The Motley Fool has a disclosure policy.

AdChoices
AdChoices

More from The Motley Fool

The Motley Fool
The Motley Fool
image beaconimage beaconimage beacon